Safety and immunogenicity of inactivated COVID-19 vaccination in adult rheumatic patients in South China: a prospective study

References

• World Health Organization. WHO coronavirus disease (COVID-19) dashboard. [ accessed 2021 Oct 16]. https://covid19.who.int/?gclid=EAIaIQobChMI2_CM6eDZ6gIVghh9Ch3nDQm1EAAYASAAEgLqwPD_BwE.
   Google Scholar
• Li L, Guo P, Zhang X, Yu Z, Zhang W, Sun H. SARS-CoV-2 vaccine candidates in rapid development. Hum Vaccin Immunother. 2021 Mar 4;17(3):1–8. doi:10.1080/21645515.2020.1804777.
   PubMed Web of Science ®Google Scholar
• Akiyama S, Hamdeh S, Micic D, et al. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. Ann Rheum Dis.2020 Oct 13;80:384–391. annrheumdis-2020-218946
   PubMed Web of Science ®Google Scholar
• Friedman MA, Winthrop KL. Vaccines and disease-modifying antirheumatic drugs: practical implications for the rheumatologist. Rheum Dis Clin North Am. 2017;43(1):1–13. doi:10.1016/j.rdc.2016.09.003.
   PubMed Web of Science ®Google Scholar
• Sanchez-Piedra C, Diaz-Torne C, Manero J, Pego-Reigosa JM, Rúa-Figueroa Í, Gonzalez-Gay MA, Gomez-Reino J, Alvaro-Gracia JM. Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. Ann Rheum Dis. 2020;79(7):988–990. doi:10.1136/annrheumdis-2020-217948.
   PubMed Web of Science ®Google Scholar
• Holvast A, Huckriede A, Wilschut J, et al. Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann Rheum Dis. 2006;65(7):913–918. doi:10.1136/ard.2005.043943.
   PubMed Web of Science ®Google Scholar
• van Aalst M, Langedijk AC, Spijker R, et al. The effect of immunosuppressive agents on immunogenicity of pneumococcal vaccination: a systematic review and meta-analysis. Vaccine. 2018 Sep 18;36(39):5832–5845. doi:10.1016/j.vaccine.2018.07.039.
   PubMed Web of Science ®Google Scholar
• Park JK, Lee EB, Shin K, et al. Korean college of rheumatology task force for COVID-19 vaccine guidance for patients with autoimmune inflammatory rheumatic diseases. COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: clinical guidance of the Korean college of rheumatology. J Korean Med Sci. 2021 Mar 29;36(12):e95. doi:10.3346/jkms.2021.36.e95.
   PubMed Web of Science ®Google Scholar
• Schulze-Koops H, Krüger K, Hoyer BF, Leipe J, Iking-Konert C, Specker C. Commission for pharmacotherapy and the board of directors of the German society for rheumatology. Updated recommendations of the German society for rheumatology for the care of patients with inflammatory rheumatic diseases in times of SARS-CoV-2-methodology, key messages and justifying information. Rheumatology (Oxford). 2021 May 14;60(5):2128–2133. doi:10.1093/rheumatology/keab072.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Johnson SR, Anthony DD, Arasaratnam RJ, Baden LR, Bass AR, Calabrese C, Gravallese EM, Harpaz R, Kroger A, et al. American college of rheumatology guidance for COVID-19 vaccination in patients with rheumatic and Musculoskeletal diseases: version 3. Arthritis Rheumatol. 2021;73(10):e60–e75. doi:10.1002/art.41928.
   PubMed Web of Science ®Google Scholar
• Medeiros-Ribeiro AC, Aikawa NE, Saad CGS, Yuki EFN, Pedrosa T, Fusco SRG, Rojo PT, Pereira RMR, Shinjo SK, Andrade DCO, et al. Immunogenicity and safety of the Corona Vac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial. Nat Med. 2021;27(10):1744–1751. doi:10.1038/s41591-021-01469-5.
   PubMed Web of Science ®Google Scholar
• Seyahi E, Bakhdiyarli G, Oztas M, Kuskucu MA, Tok Y, Sut N, Ozcifci G, Ozcaglayan A, Balkan II, Saltoglu N, et al. Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly. Rheumatol Int. 2021;41(8):1429–1440. doi:10.1007/s00296-021-04910-7.
   PubMed Web of Science ®Google Scholar
• Stowe RP, Peek MK, Cutchin MP, Goodwin JS. Plasma cytokine levels in a population-based study: relation to age and ethnicity. J Gerontol a Biol Sci Med Sci. 2010;65(4):429–433. doi:10.1093/gerona/glp198.
   PubMed Web of Science ®Google Scholar
• Moyon Q, Sterlin D, Miyara M, Anna F, Mathian A, Lhote R, Ghillani-Dalbin P, Breillat P, Mudumba S, de Alba S, et al. Bnt162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus. Ann Rheum Dis. 2021 Oct 4;81(4):575–583: annrheumdis-2021-221097. doi:10.1136/annrheumdis-2021-221097.
   PubMed Web of Science ®Google Scholar
• Ruddy JA, Connolly CM, Boyarsky BJ, Werbel WA, Christopher-Stine L, Garonzik-Wang J, Segev DL, Paik JJ. High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2021;80(10):1351–1352. doi:10.1136/annrheumdis-2021-220656.
   PubMed Web of Science ®Google Scholar
• Haberman RH, Herati R, Simon D, Samanovic M, Blank RB, Tuen M, Koralov SB, Atreya R, Tascilar K, Allen JR, et al. Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. Ann Rheum Dis. 2021;80(10):1339–1344. doi:10.1136/annrheumdis-2021-220597. Epub 2021 May 25. PMID: 34035003; PMCID: PMC8219484
   PubMed Web of Science ®Google Scholar
• Hua C, Barnetche T, Combe B, Morel J. Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2014;66(7):1016–1026. doi:10.1002/acr.22246. PMID: 24339395.
   PubMed Web of Science ®Google Scholar
• Chan ES, Cronstein BN. Methotrexate—how does it really work? Nat Rev Rheumatol. 2010;6(3):175–178. doi:10.1038/nrrheum.2010.5. PMID: 20197777.
   PubMed Web of Science ®Google Scholar
• Burns CM. The history of cortisone discovery and development. Rheum Dis Clin North Am. 2016;42(1):1–14, vii. doi:10.1016/j.rdc.2015.08.001. PMID: 26611547.
   PubMed Web of Science ®Google Scholar
• Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16(3):155–166. doi:10.1038/s41584-020-0372-x. Epub 2020 Feb 7. PMID: 32034323.
   PubMed Web of Science ®Google Scholar
• Mohammadi O, Ta K. Azathioprine. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing ; 2022. https://www.ncbi.nlm.nih.gov/books/NBK542190/. 2022 Jan. PMID: 31194347
   Google Scholar
• Prakash A, Jarvis B. Leflunomide: a review of its use in active rheumatoid arthritis. Drugs. 1999;58(6):1137–1164. doi:10.2165/00003495-199958060-00010. PMID: 10651393.
   PubMed Web of Science ®Google Scholar
• Mucke HA. Iguratimod: a new disease-modifying antirheumatic drug. Drugs Today (Barc). 2012;48(9):577–586. doi:10.1358/dot.2012.48.9.1855758. PMID: 23032798.
   PubMed Web of Science ®Google Scholar
• Prasad N, Manjunath R, Rangaswamy D, Jaiswal A, Agarwal V, Bhadauria D, Kaul A, Sharma R, Gupta A. Efficacy and safety of cyclosporine versus tacrolimus in steroid and cyclophosphamide resistant nephrotic syndrome: a prospective study. Indian J Nephrol. 2018;28(1):46–52. doi:10.4103/ijn.IJN_240_16. PMID: 29515301; PMCID: PMC5830809.
   PubMed Web of Science ®Google Scholar
• Gadina M, Le MT, Schwartz DM, Silvennoinen O, Nakayamada S, Yamaoka K, O’-Shea JJ. Janus kinases to jakinibs: from basic insights to clinical practice. Rheumatology (Oxford). 2019 Feb 1;58(Suppl 1):i4–i16. doi:10.1093/rheumatology/key432; PMID: 30806710; PMCID: PMC6657570
   PubMedGoogle Scholar
• Gerriets V, Goyal A, Khaddour K. Tumor necrosis factor inhibitors. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Apr 30. https://www.ncbi.nlm.nih.gov/books/NBK482425/. 2022 Jan. PMID: 29494032
   Google Scholar
• Fobelo Lozano MJ, Serrano Giménez R, Castro Fernández M. Emergence of inflammatory bowel disease during treatment with secukinumab. J Crohns Colitis. 2018 Aug 29;12(9):1131–1133. doi:10.1093/ecco-jcc/jjy063; PMID: 29746636
   PubMed Web of Science ®Google Scholar
• Jordan N, D’-Cruz DP. Belimumab for the treatment of systemic lupus erythematosus. Expert Rev Clin Immunol. 2015;11(2):195–204. doi:10.1586/1744666X.2015.996550. Epub 2014 Dec 29. PMID: 25543845.
   PubMed Web of Science ®Google Scholar
• Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, van Assen S, Bijl M, Breedveld FC, D’Amelio R, Dougados M, Kapetanovic MC, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39–52. doi:10.1136/annrheumdis-2019-215882.
   PubMed Web of Science ®Google Scholar
• Ramasamy MN, Jessop LJ. CoronaVac: more data for regulators and policy makers. Lancet. 2021 Jul 17;398(10296):186–188. doi:10.1016/S0140-6736(21)01543-9.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, Han W, Chen Z, Tang R, Yin W, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(2):181–192. doi:10.1016/S1473-3099(20)30843-4.
   PubMed Web of Science ®Google Scholar
• R A, Wang H, Wang W, Tan W. Summary of the detection kits for SARS-CoV-2 approved by the national medical products administration of China and their application for diagnosis of COVID-19. Virol Sin. 2020;35(6):699–712. doi:10.1007/s12250-020-00331-1. Epub 2020 Dec 22. PMID: 33351166; PMCID: PMC7754703.
   PubMed Web of Science ®Google Scholar
• Nand IS, Fisher LD, Chiang Y-T, Latini R, Masson S, Maggioni AP, Glazer RD, Tognoni G, Cohn JN. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2003;107(9):1278–1283. doi:10.1161/01.CIR.0000054164.99881.00.
   PubMed Web of Science ®Google Scholar
• Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology(STROBE) statement: guidelines for reporting observational studies. The The Lancet. 2007;370(9596):1453–1457. doi:10.1016/S0140-6736(07)61602-X.
   PubMed Web of Science ®Google Scholar
• WHO Coronavirus (COVID-19) Dashboard with vaccination data. WHO; 2021. https://covid19.who.int.
   Google Scholar
• Kumar S, Çalışkan DM, Janowski J, Faist A, Conrad BCG, Lange J, Ludwig S, Brunotte L. Beyond vaccines: clinical status of prospective COVID-19 therapeutics. Front Immunol. 2021 Oct 1;12:752227. doi:10.3389/fimmu.2021.752227.
   PubMed Web of Science ®Google Scholar
• Bueno SM, Abarca K, González PA, Gálvez NMS, Soto JA, Duarte LF, Schultz BM, Pacheco GA, González LA, Vázquez Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in a subgroup of healthy adults in Chile. Clin Infect Dis. 2021 Sep 19: ciab823. doi:10.1093/cid/ciab823.
   Google Scholar
• Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21(1):39–51. doi:10.1016/S1473-3099(20)30831-8.
   PubMed Web of Science ®Google Scholar
• Furer V, Eviatar T, Zisman D, Peleg H, Paran D, Levartovsky D, Zisapel M, Elalouf O, Kaufman I, Meidan R, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis.2021;80(10):1330–1338. doi:10.1136/annrheumdis-2021-220647.
   PubMed Web of Science ®Google Scholar
• Boyarsky BJ, Ruddy JA, Connolly CM, Ou MT, Werbel WA, Garonzik-Wang JM, Segev DL, Paik JJ. Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2021 Mar 23;80(8):1098–1099: annrheumdis-2021-220289. doi:10.1136/annrheumdis-2021-220289.
   PubMed Web of Science ®Google Scholar
• Zhao T, Shen J, Zhu Y, Tian X, Wen G, Wei Y, Xu B, Fu C, Xie Z, Xi Y, et al. Immunogenicity of inactivated SARS-CoV-2 vaccines in patients with rheumatoid arthritis: a case series. Front Public Health. 2022 Apr 25;10:875558. doi:10.3389/fpubh.2022.875558. PMID: 35548080; PMCID: PMC9081335
   PubMed Web of Science ®Google Scholar
• Li X, Tong X, Yeung WWY, Kuan P, Yum SHH, Chui CSL, Lai FTT, Wan EYF, Wong CKH, Chan EWY, et al. Two-Dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong. Ann Rheum Dis. 2022;81(4):564–568. doi:10.1136/annrheumdis-2021-221571. Epub 2021 Oct 22. PMID: 34686479; PMCID: PMC8550868
   PubMed Web of Science ®Google Scholar
• Boekel L, Steenhuis M, Hooijberg F, et al. Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies. Lancet Rheumatol 2021 Aug 6; 3(11): 778–788. doi:10.1016/S2665-9913(21)00222-8.
   Google Scholar
• Lee H, Kong SY, Sohn JY, et al. Elevated red blood cell distribution width as a simple prognostic factor in patients with symptomatic multiple myeloma. Biomed Res Int. 2014;2014:145619. doi:10.1155/2014/145619.
   PubMed Web of Science ®Google Scholar
• Wang H, Wang J, Huang R, Xia J, Zuo L, Yan X, Yang Y, Wu C. Red blood cell distribution width for predicting significant liver inflammation in patients with autoimmune hepatitis. Eur J Gastroenterol Hepatol. 2019;31(12):1527–1532. doi:10.1097/MEG.0000000000001447.
   PubMed Web of Science ®Google Scholar
• Balandya E, Reynolds T, Obaro S, Makani J. Alteration of lymphocyte phenotype and function in sickle cell anemia: implications for vaccine responses. Am J Hematol. 2016;91(9):938–946. doi:10.1002/ajh.24438.
   PubMed Web of Science ®Google Scholar
• Frasca D, Blomberg BB. Aging induces B cell defects and decreased antibody responses to influenza infection and vaccination. Immun Ageing. 2020 Nov 19;17(1):37. doi:10.1186/s12979-020-00210-z.
   PubMed Web of Science ®Google Scholar
• Deepak P, Kim W, Paley MA, et al. Effect of Immunosuppression on the immunogenicity of mRNA vaccines to SARS-CoV-2 : a prospective cohort study Ann Intern Med2021 Aug 31;174 (11):1572–1585. doi:10.7326/M21-1757.
   PubMed Web of Science ®Google Scholar
• Haberman RH, Herati RS, Simon D, et al. Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. Ann Rheum Dis. 2021;80(10): 1339–1344. doi:10.1136/annrheumdis-2021-220597.
   PubMed Web of Science ®Google Scholar
• Aikawa NE, Campos LM, Silva CA, Carvalho JF, Saad CGS, Trudes G, Duarte A, Miraglia JL, Timenetsky MDCS, Viana VST, et al. Glucocorticoid: major factor for reduced immunogenicity of 2009 influenza a (H1N1) vaccine in patients with juvenile autoimmune rheumatic disease. J Rheumatol. 2012;39(1):167–173. doi:10.3899/jrheum.110721.
   PubMed Web of Science ®Google Scholar
• Bugatti S, De Stefano L, Balduzzi S, Greco MI, Luvaro T, Cassaniti I, Bogliolo L, Mazzucchelli I, D’-Onofrio B, di Lernia M, et al. Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis. Ann Rheum Dis. 2021;80(12):1635–1638. doi:10.1136/annrheumdis-2021-220862.
   PubMed Web of Science ®Google Scholar
• Sakuraba A, Luna A, Micic D. Serologic response to coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis. Gastroenterology. 2021 Sep 29;162(1): 88–108. doi:10.1053/j.gastro.2021.09.055.
   PubMed Web of Science ®Google Scholar
• Nozaki YI. Novel molecular insights and a new csDMARD for rheumatoid arthritis, from Japan to the world. Life (Basel). 2021 May 20;11(5):457.
   PubMed Web of Science ®Google Scholar
• Oliver SE, Gargano JW, Scobie H, Wallace M, Hadler SC, Leung J, Blain AE, McClung N, Campos-Outcalt D, Morgan RL, et al. The advisory committee on immunization practices’ interim recommendation for use of Janssen COVID-19 vaccine — United States, February 2021. MMWR Morb Mortal Wkly Rep. 2021 Mar 5;70(9):329–332. doi:10.15585/mmwr.mm7009e4.
   PubMed Web of Science ®Google Scholar
• Damasceno DHP, Amaral AA, Silva CA, Simões E, Silva AC. The impact of vaccination worldwide on SARS-CoV-2 infection: A review on vaccine mechanisms, results of clinical trials, vaccinal coverage and interactions with novel variants. Curr Med Chem. 2022 Sep 1; 29(15):2673–2690. doi:10.2174/0929867328666210902094254.
   PubMed Web of Science ®Google Scholar
• Shibata K, Tanaka H, Otani A, Kubo M, Hasegawa A, Amano I. Development of thrombocytopenic purpura following BNT162b2 mRNA COVID-19 vaccination. Rinsho Ketsueki. 2021;62(10):1519–1521. doi:10.11406/rinketsu.62.1519.
   PubMedGoogle Scholar
• Bozkurt B, Kamat I, Hotez PJ. Myocarditis with COVID-19 mRNA vaccines. Circulation. 2021 Aug 10;144(6):471–484. doi:10.1161/CIRCULATIONAHA.121.056135.
   PubMed Web of Science ®Google Scholar
• Li X, Ostropolets A, Makadia R, et al. Characterizing the incidence of adverse events of special interest for COVID-19 vaccines across eight countries: a multinational network cohort study. medRxiv[Preprint]. 2021 Apr 17:03.25.21254315. doi:10.1101/2021.03.25.21254315.
   Google Scholar
• Chiang TP, Connolly CM, Ruddy JA, Boyarsky BJ, Alejo JL, Werbel WA, Massie A, Christopher-Stine L, Garonzik-Wang J, Segev DL, et al. Antibody response to the Janssen/Johnson & Johnson SARS-CoV-2 vaccine in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2021;80(10):1365–1366. doi:10.1136/annrheumdis-2021-221145.
   PubMed Web of Science ®Google Scholar
• Li D, Sempowski GD, Saunders KO, Acharya P, Haynes BF. SARS-CoV-2 neutralizing antibodies for COVID-19 prevention and treatment. Annu Rev Med. 2022 Jan 27;73(1):1–16. doi:10.1146/annurev-med-042420-113838. Epub 2021 Aug 24. PMID: 34428080
   PubMedGoogle Scholar